Patents by Inventor Soosung Kang

Soosung Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • JAK INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
    Publication number: 20220220109
    Abstract: The present invention relates to a JAK inhibitor compound and a pharmaceutical composition including the same. More specifically, the present invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutical composition including the same. The structure of the compound of Formula I is described in the specification. The compound of the present invention can exhibit therapeutic effects on a variety of diseases, for example, inflammatory diseases, autoimmune diseases, myeloproliferative diseases, and human cancers due to its ability to regulate signal transduction at the level of JAK kinases.
    Type: Application
    Filed: May 27, 2020
    Publication date: July 14, 2022
    Inventors: Soosung KANG, Eun Sun PARK, Eun Hee PARK, Seung Hee HAN
  • Mammalian and bacterial nitric oxide synthase inhibitors
    Patent number: 9951014
    Abstract: Compounds and related methods for inhibition of mammalian and bacterial nitric oxide synthase.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: April 24, 2018
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Qing Jing, Soosung Kang, Heng-Yen Wang
  • SELECTIVE CALCIUM CHANNEL ANTAGONISTS
    Publication number: 20160310491
    Abstract: The present invention relates to compositions and methods for the treatment and/or prevention of neurodegenerative disorders, e.g., Parkinson's disease (PD). In particular, the present invention provides compositions comprising selective antagonists of calcium ion channels (e.g., cav1.3-type ion channels), and methods of use thereof to treat or prevent neurodegenerative disorders.
    Type: Application
    Filed: July 1, 2016
    Publication date: October 27, 2016
    Inventors: Dalton J. Surmeier, JR., Richard B. Silverman, Soosung Kang, Garry Cooper
  • Selective calcium channel antagonists
    Patent number: 9428467
    Abstract: The present invention relates to compositions and methods for the treatment and/or prevention of neurodegenerative disorders, e.g., Parkinson's disease (PD). In particular, the present invention provides compositions comprising selective antagonists of calcium ion channels (e.g., cav1.3-type ion channels), and methods of use thereof to treat or prevent neurodegenerative disorders.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: August 30, 2016
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Dalton J. Surmeier, Jr., Richard B. Silverman, Soosung Kang, Garry Cooper
  • Mammalian and Bacterial Nitric Oxide Synthase Inhibitors
    Publication number: 20160122302
    Abstract: Compounds and related methods for inhibition of mammalian and bacterial nitric oxide synthase.
    Type: Application
    Filed: November 4, 2015
    Publication date: May 5, 2016
    Inventors: Richard B. Silverman, Qing Jing, Soosung Kang, Heng-Yen Wang
  • Prodrugs of Fluorinated Mevalonates to Inhibit the Mevalonate Pathway of Streptococcus pneumoniae
    Publication number: 20160024042
    Abstract: Fluorinated prodrug compounds as can be used for selective streptococcal mevalonate pathway inhibition.
    Type: Application
    Filed: October 6, 2015
    Publication date: January 28, 2016
    Inventors: Richard B. Silverman, Mizuki Watanabe, Soosung Kang, Thomas S. Leyh
  • Prodrugs of fluorinated mevalonates to inhibit the mevalonate pathway of
    Patent number: 9150534
    Abstract: Fluorinated prodrug compounds as can be used for selective streptococcal mevalonate pathway inhibition.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: October 6, 2015
    Assignees: Northwestern University, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Richard B. Silverman, Mizuki Watanabe, Soosung Kang, Thomas S. Leyh
  • Prodrugs of Fluorinated Mevalonates to Inhibit the Mevalonate Pathway of Streptococcus pneumoniae
    Publication number: 20130245284
    Abstract: Fluorinated prodrug compounds as can be used for selective streptococcal mevalonate pathway inhibition.
    Type: Application
    Filed: February 28, 2013
    Publication date: September 19, 2013
    Inventors: Richard B. Silverman, Mizuki Watanabe, Soosung Kang
  • SELECTIVE CALCIUM CHANNEL ANTAGONISTS
    Publication number: 20120196883
    Abstract: The present invention relates to compositions and methods for the treatment and/or prevention of neurodegenerative disorders, e.g., Parkinson's disease (PD). In particular, the present invention provides compositions comprising selective antagonists of calcium ion channels (e.g., cav1.3-type ion channels), and methods of use thereof to treat or prevent neurodegenerative disorders.
    Type: Application
    Filed: January 19, 2012
    Publication date: August 2, 2012
    Inventors: Dalton J. Surmeier, JR., Richard B. Silverman, Soosung Kang, Garry Cooper